Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)

NCT07784270 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07784270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07784270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
August 20, 2026
Completion date
August 8, 2028
Enrollment
1,500 (estimated)
Sites
227

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, obesity or overweight